Larimar Therapeutics, Inc. (LRMR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-55.3%

$1.06

vs $2.37 price

Levered DCF

$1.12

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-2.84

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.68×	-2.93×	-5.42×	-3.11×	-3.68×	-6.01×	-5.31×	-2.6×
P/B	3.56×	1.38×	2.44×	0.96×	2.88×	2.84×	-176.84×	1.71×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-1.19×	-2.6×	-4.87×	-2.43×	-2.41×	-4.52×	-5.27×	-2.15×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	2.19×	8.02×	9.49×	11.28×	8.16×	10.89×	0.81×	9.12×
Debt / equity	0.05×	0.03×	0.07×	0.05×	0.09×	0.07×	-0.14×	0.22×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-212.2%	-46.9%	-45.2%	-31.9%	-78.6%	-47.2%	3333.1%	-65.8%
Return on invested capital	-210.0%	-51.4%	-47.9%	-31.4%	-71.7%	-44.5%	3888.4%	-53.7%
Return on assets	-113.6%	-40.3%	-38.5%	-28.0%	-64.4%	-40.4%	-444.8%	-50.4%
Free cash flow yield	-40.8%	-30.1%	-16.8%	-26.0%	-22.9%	-16.6%	-18.6%	-32.3%
Earnings yield	-59.6%	-34.0%	-18.5%	-33.2%	-27.3%	-16.6%	-18.8%	-38.5%
Enterprise value	$196.6M	$209M	$178.5M	$85M	$121.1M	$192.8M	$121.8M	$130.8M
Net debt / EBITDA	0.49×	0.35×	0.58×	0.61×	1.27×	1.45×	0.04×	0.47×
Cash conversion cycle (days)	0	0	0	0	0	-6,203	-16,561	-1,271